The company uses its proprietary drug discovery platform, MINE, to identify biotherapeutic candidates called Probiomics that stimulate the innate immune response. These candidates have potential applications in areas such as chronic inflammatory skin diseases, gastrointestinal diseases, and eye diseases. Quorum Innovations also has an anti-aging skin health product line called BioEsse®. Their technology aims to treat barrier deficiency states and engage the body's immune system to address antibiotic resistance. The company is in the early stage with a licensing agreement, a consumer product in production, and ongoing development plans for medical indications. Their products range from direct-to-consumer to medical device to traditional pharmaceutical.